

Figure S1. ATO and Eto treatment chronology-dependent viability reduction in the RD-ES cell line. RD-ES cells were treated with ATO (A2) and Eto (E0.5) at the doses indicated ( $\mu\text{M}$ ). Medium change was performed after 48 or 72 h. In case of pre-treatment, the drug was replaced with the medium change, whereas in all other cases the previous treatment was continued. The graph shows the mean values and standard deviations of four independent experiments. Viability of the mock-treated control was set to 100. Significant differences between groups are indicated by small letters. 'a' indicates a reduction of viability with  $P \leq 0.001$  compared to all other treatments; 'b' indicates enhanced viability with  $P \leq 0.001$  compared to all other treatments; 'c' indicates enhanced viability with  $P \leq 0.05$  compared to all other treatments. ATO, arsenic trioxide; Eto, etoposide.

